Drug Targets for Bladder Cancer

Drug Targets PD1/PD-L1 for Bladder Cancer with Approved Drugs

Drug target Cancer drugs Company
PD-1 Pembrolizumab Merck
PD-1 Nivolumab Bristol-Myers Squibb
PD-L1 Atezolizumab Genentech/Roche

PD-1 is an immunoreceptor expressed in surface of T lymphocytes, B-lymphocytes and monocytes. PD-L1 and PD-L2 are the ligands for PD-1 and are expressed in normal tissues such as heart, lung and placenta. Binding of PD-1 to PD-L1 or PD-L2 results in negative regulation of T-cell signaling and activation. Cancer cells also express PD-L1 and overexpression PD-L1 by tumors inhibit T-cell-mediated antitumor effect. PD-1 inhibitors and PD-L1 inhibitors are antibodies that bind to PD-1 receptor in T cells and PD-L1 receptors in tumor, respectively, thereby inhibiting interaction between PD-1 and PD-L1 and enhancing the T-cell-mediated antitumor response. multiple studies on bladder cancer cell lines and cystectomy tumor specimens concluded that expression of PD-L1 is significant in urothelial cancer and correlates with disease severity and outcome. In 2006, Nakanishi et al. evaluated samples from 67 patients who underwent surgical resection for urothelial cancer for the expression of PD-1 and PD-L1. They demonstrated that the expression of PD-L1 (B7-H1) was substantial in all tested urothelial cancers specimens and noted that higher the tumor grades had higher the expression of PD-L1. Tumor associated PD-L1 expression was significantly associated with a high frequency of postoperative recurrence and poor survival rate.(Sundararajan S, et al. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?[J]. Future Oncology, 2015, 11(16): 2299-2306.)

Drug targets for Bladder cancer: Related Information